Eaton Vance Worldwide Health Sci R (ERHSX)
15.70
+0.07 (+0.45%)
USD |
Jul 22
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.48% | 1.136B | 0.17% | 38.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -90.96M | 17.49% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies principally engaged in the discovery, development, production or distribution of products related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies. It has a policy of investing at least 25% of its assets in investments in the medical research and health care industry. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | ETHSX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Eaton Vance |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Jason Kritzer | 5.00 yrs |
| Samantha Pandolfi | 5.00 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
74
-90.96M
-4.645B
Category Low
7.623B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of June 30, 2021
Performance Versus Category
As of July 22, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of July 22, 2021.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Johnson & Johnson | 8.07% | 171.79 | 1.06% |
| UnitedHealth Group Inc | 7.35% | 417.68 | 0.46% |
| AbbVie Inc | 4.49% | 118.06 | 0.44% |
|
Roche Holding AG
|
4.01% | -- | -- |
| Eli Lilly and Co | 3.92% | 244.41 | 2.48% |
| Medtronic PLC | 3.83% | 128.56 | 1.14% |
|
Sanofi SA
|
3.78% | -- | -- |
| Thermo Fisher Scientific Inc | 3.63% | 532.18 | 1.46% |
|
AstraZeneca PLC
|
3.57% | -- | -- |
| Merck & Co Inc | 3.22% | 77.50 | 1.27% |
Basic Info
| Investment Strategy | |
| The investment seeks long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies principally engaged in the discovery, development, production or distribution of products related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies. It has a policy of investing at least 25% of its assets in investments in the medical research and health care industry. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | ETHSX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Eaton Vance |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Jason Kritzer | 5.00 yrs |
| Samantha Pandolfi | 5.00 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (7-22-21) | 0.17% |
| 30-Day SEC Yield (4-30-10) | Upgrade |
| 7-Day SEC Yield (5-25-10) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 27.29 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of May 31, 2021
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 9/8/2003 |
| Last Annual Report Date | 8/31/2020 |
| Last Prospectus Date | 1/1/2021 |
| Share Classes | |
| ECHSX | C |
| EIHSX | Inst |
| ETHSX | A |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |